C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 38/16 (2006.01) A61K 39/395 (2006.01) C07K 14/435 (2006.01) C07K 14/575 (2006.01) C07K 16/18 (2006.01) C07K 16/42 (2006.01) C12N 15/63 (2006.01) G01N 33/53 (2006.01) G01N 33/68 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2338561
The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N- terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid. Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or the vector of the present invention. Also described are a method for producing the antagonist of the present invention, antibodies directed the antagonist of the present invention, as well as anti-idiotypic antibodies directed against the antibody of the present invention. The present invention also relates to pharmaceutical and diagnostic compositions comprising the antagonist, the polynucleotide, the vector, the antibody, and/or the anti-idiotypic antibody of the present invention. Furthermore, the present invention relates to a kit comprising one or more of the above mentioned compounds of the present invention and to the use of one or more of these compounds for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin- Releasing Factor Receptor, type 2 (CRFR2)-associated disease.
L'invention a trait à un antagoniste du ligand du récepteur de la corticolibérine de type 2 (CRFR2) auquel il manque les acides aminés N-terminaux 8 à 10 de sauvagine native. L'invention a également trait à un antagoniste du ligand du récepteur de la corticolibérine de type 2 (CRFR2) auquel il manque les acides aminés N-terminaux 11 de sauvagine native, l'acide aminé N-terminal dudit antagoniste étant un acide aminé chargé. De plus, l'invention a trait à un polynucléotide codant pour l'antagoniste de l'invention, un vecteur comprenant le polynucléotide de l'invention, et un hôte comprenant le polynucléotide ou le vecteur de l'invention. L'invention concerne également un procédé de production de l'antagoniste de l'invention, des anticorps dirigés contre l'antagoniste de l'invention, ainsi que des anticorps anti-idiotypiques dirigés contre l'anticorps de l'invention. L'invention concerne également des compositions pharmaceutiques et diagnostiques renfermant l'antagoniste, le polynucléotide, le vecteur, l'anticorps, et/ou l'anticorps anti-idiotypique de l'invention. De plus, l'invention a trait à une trousse comportant un ou plusieurs des composés susmentionnés de l'invention, et à l'utilisation d'un ou de plusieurs de ces composés pour préparer une composition pharmaceutique servant à prévenir et/ou à traiter une maladie associée au récepteur de la corticolibérine de type 2 (CRFR2).
Ruhmann Andreas
Spiess Joachim
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.v.
Ridout & Maybee Llp
LandOfFree
Antagonists specific for the corticotropin-releasing factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists specific for the corticotropin-releasing factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists specific for the corticotropin-releasing factor... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1583761